H A Weizel

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

Irene L. Andrulis, Shelley B. Bull, Martin E. Blackstein et al. · Journal of Clinical Oncology · 1998 · 447 citations

Medicine, Oncology, Pathology +16

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.

Kathleen I. Pritchard, Alexander Paterson, Shai Fine et al. · Journal of Clinical Oncology · 1997 · 94 citations

Medicine, Oncology, Pharmacotherapy +17

Bacterial Action in Development of Irreversibility to Transfusion in Hemorrhagic Shock in the Dog

S. Jacob, H A Weizel, Ethel J. Gordon et al. · American Journal of Physiology-Legacy Content · 1954 · 64 citations

Medicine, Hematology, Microbiology +11

Effect of Norepinephrine on Circulation of the Dog in Hemorrhagic Shock

E.D. Frank, Howard A. Frank, S. W. Jacob et al. · American Journal of Physiology-Legacy Content · 1956 · 43 citations

Medicine, Hematology, Veterinary Physiology +16

Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.

Paul E. Goss, Roy M. Clark, U Ambus et al. · PubMed · 1995 · 37 citations

Medicine, Oncology, Pharmacology +17